Assertio Holdings IncNASDAQ:ASRT
- LAST PRICE1.0350
- TODAY'S CHANGE (%)0.0437 (4.4084%)
- Bid / Lots1.0300/ 6
- Ask / Lots1.0400/ 3
- Open / Previous Close0.9913 / 0.9913
- Day Range
- 52 Week Range
- Volume168,905
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ASRT |
|---|---|---|
| 09:32 ET | 14161 | 0.98565 |
| 09:34 ET | 6941 | 0.975 |
| 09:36 ET | 1550 | 0.9725 |
| 09:38 ET | 200 | 0.97 |
| 09:39 ET | 702 | 0.971 |
| 09:41 ET | 8007 | 0.963 |
| 09:43 ET | 5173 | 0.970999 |
| 09:45 ET | 4586 | 0.962 |
| 09:48 ET | 1600 | 0.971001 |
| 09:50 ET | 2900 | 0.97 |
| 09:52 ET | 1500 | 0.97 |
| 09:54 ET | 799 | 0.9715 |
| 09:56 ET | 100 | 0.9715 |
| 09:57 ET | 100 | 0.98 |
| 09:59 ET | 1400 | 0.98 |
| 10:01 ET | 2895 | 0.973 |
| 10:03 ET | 500 | 0.9751 |
| 10:06 ET | 6325 | 0.99 |
| 10:08 ET | 200 | 0.99 |
| 10:10 ET | 200 | 0.99 |
| 10:12 ET | 300 | 0.9816 |
| 10:14 ET | 923 | 0.9816 |
| 10:15 ET | 200 | 0.99 |
| 10:17 ET | 1195 | 0.99 |
| 10:19 ET | 1350 | 0.99 |
| 10:24 ET | 626 | 0.9816 |
| 10:26 ET | 900 | 0.9816 |
| 10:28 ET | 500 | 0.9801 |
| 10:30 ET | 925 | 0.99 |
| 10:32 ET | 5107 | 1.01 |
| 10:33 ET | 17870 | 1.015 |
| 10:35 ET | 2095 | 1.03 |
| 10:37 ET | 12938 | 1.03 |
| 10:39 ET | 14259 | 1.035 |
| 10:42 ET | 6513 | 1.025 |
| 10:44 ET | 8239 | 1.025 |
| 10:46 ET | 200 | 1.025 |
| 10:50 ET | 300 | 1.03 |
| 10:51 ET | 17695 | 1.05 |
| 10:55 ET | 750 | 1.04 |
| 10:57 ET | 500 | 1.035 |
| 11:00 ET | 617 | 1.035 |
| 11:02 ET | 405 | 1.031 |
| 11:04 ET | 200 | 1.035 |
| 11:06 ET | 1100 | 1.035 |
| 11:08 ET | 300 | 1.035 |
| 11:09 ET | 300 | 1.035 |
| 11:11 ET | 278 | 1.035 |
Jun 6, 2024
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 4:06PM ET on Thursday Jun 06, 2024 by Dow Jones
4:06PM ET on Thursday Jun 06, 2024 by Dow Jones
Jun 5, 2024
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024, from 8:30AM ET on Wednesday Jun 05, 2024 by Dow Jones
8:30AM ET on Wednesday Jun 05, 2024 by Dow Jones
May 29, 2024
Assertio Announces the Appointment of Brendan P. O'Grady as New CEO, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow JonesPress Release: Assertio Announces the Appointment of Brendan P. O'Grady as New CEO, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
DJ Assertio Holdings Initiated at Buy by Alliance Global Partners, from 1:10PM ET on Tuesday May 28, 2024 by Dow Jones
1:10PM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Assertio Holdings Inc | 95.1M | -0.3x | --- |
Natural Alternatives International Inc | 40.3M | -11.6x | -18.19% |
SCYNEXIS Inc | 88.0M | 1.1x | --- |
American Oriental Bioengineering Inc | 30.0 | 0.0x | --- |
Bavarian Nordic A/S | 2.1B | 13.6x | --- |
Takeda Pharmaceutical Co Ltd | 43.1B | 46.1x | -8.01% |
Company Information
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Contact Information
- Headquarters
- 100 S. Saunders Road, Suite 300LAKE FOREST, IL, United States 60045
- Phone
- 224-419-7106
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Peter Staple
- Chief Executive Officer, Director
- Brendan O'Grady
- Chief Financial Officer, Senior Vice President, Chief Accounting Officer
- Ajay Patel
- Senior Vice President, General Counsel, Executive Officer
- Sam Schlessinger
- Senior Vice President and Chief Commercial Officer
- Paul Schwichtenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $95.1M |
|---|---|
Revenue (TTM) | $142.1M |
Shares Outstanding | 95.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-3.95 |
Book Value | $1.46 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -177.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
